September 27, 2022

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization

September 19, 2022

BioLineRx Announces $15 Million Registered Direct Offering

September 15, 2022

BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital